homepage-top-section

As part of the collaboration, both the companies will co-develop AVT23, an investigational compound, that is now in late development stage. The companies will develop the proposed biosimilar

Cabenuva has now been cleared for every-two-month dosing for the treatment of HIV-1 in people who are virologically suppressed on a stable regimen, with no prior treatment failure,

The protein-based vaccine candidate is intended to immunise individuals aged 18 years and above against Covid-19. Developed using Novavax’ recombinant nanoparticle technology, NVX-CoV2373 is engineered from the genetic

The drug is intended to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) in

The biopharmaceutical company stated that the dormant vaccine manufacturing site would add new capabilities to its medicine portfolio of Canadian and US companies. It is expected to allow

The US regulator has accepted the company’s supplemental new drug application (sNDA) for Evrysdi to treat SMA in pre-symptomatic babies, aged below two months. Evrysdi is a survival

As part of the collaboration, the US-based company will use its Library of Libraries for the discovery of new antibodies against Artisan Bio’s immunotherapy targets. Meanwhile, Artisan will

The acquisition will help accelerate the company’s growth and establish a footprint in the menopause market. Previously, Amyris announced plans to establish a new consumer brand to offer

APS03118 is a second generation selective rearranged during transfection (RET) inhibitor that targets patients suffering with non-small cell lung cancer, breast cancer, ovarian cancer, thyroid cancer, colorectal cancer,